S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in
NASDAQ:SPPI

Spectrum Pharmaceuticals Stock Forecast, Price & News

$3.79
+0.01 (+0.26 %)
(As of 10/20/2020 05:12 PM ET)
Add
Compare
Today's Range
$3.68
Now: $3.79
$3.87
50-Day Range
$3.93
MA: $4.22
$4.90
52-Week Range
$1.74
Now: $3.79
$10.57
Volume2.10 million shs
Average Volume2.19 million shs
Market Capitalization$552.33 million
P/E RatioN/A
Dividend YieldN/A
Beta2.29
Spectrum Pharmaceuticals, Inc., a biopharma company, develops and commercializes oncology and hematology drug products. The company is developing ROLONTIS, a novel long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNá, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of relapsed or refractory non-Hodgkin's lymphoma patients, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. for focused interferon therapeutics drug delivery platform. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Read More
Spectrum Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300
Employees146

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$109.33 million
Book Value$1.69 per share

Profitability

Net Income$-112,690,000.00

Miscellaneous

Market Cap$552.33 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$3.79
+0.01 (+0.26 %)
(As of 10/20/2020 05:12 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

How has Spectrum Pharmaceuticals' stock price been impacted by Coronavirus?

Spectrum Pharmaceuticals' stock was trading at $2.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SPPI stock has increased by 58.6% and is now trading at $3.79.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Spectrum Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Spectrum Pharmaceuticals
.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Spectrum Pharmaceuticals
.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its quarterly earnings results on Monday, August, 10th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.05.
View Spectrum Pharmaceuticals' earnings history
.

What price target have analysts set for SPPI?

5 Wall Street analysts have issued twelve-month target prices for Spectrum Pharmaceuticals' shares. Their forecasts range from $7.00 to $13.00. On average, they expect Spectrum Pharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 163.9% from the stock's current price.
View analysts' price targets for Spectrum Pharmaceuticals
.

Are investors shorting Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 9,930,000 shares, an increase of 40.1% from the September 15th total of 7,090,000 shares. Based on an average daily trading volume, of 3,080,000 shares, the short-interest ratio is currently 3.2 days.
View Spectrum Pharmaceuticals' Short Interest
.

Who are some of Spectrum Pharmaceuticals' key competitors?

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Opko Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the following people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 62, Pay $1.4M)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 52, Pay $937.46k)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 44, Pay $1.01M)
  • Mr. Keith M. McGahan J.D., L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 44, Pay $823.28k)
  • Dr. Francois Lebel FRCPC, M.D., Exec. VP & Chief Medical Officer (Age 68, Pay $854.04k)

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.09%), Louisiana State Employees Retirement System (0.05%) and Pacer Advisors Inc. (0.00%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga and William Ashton.
View institutional ownership trends for Spectrum Pharmaceuticals
.

Which major investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was purchased by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, State of Alaska Department of Revenue, and Pacer Advisors Inc..
View insider buying and selling activity for Spectrum Pharmaceuticals
.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $3.79.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $552.33 million and generates $109.33 million in revenue each year. The biotechnology company earns $-112,690,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Spectrum Pharmaceuticals employs 146 workers across the globe.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is www.sppirx.com.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.